Wilfried Dinh: Female CVD Risks Measurement – Why It’s not Smaller Than We Used to Think
Wilfried Dinh, Senior Clinical Program Leader at Boehringer Ingelheim, posted on LinkedIn:
“Women’s cardiovascular risk is not “smaller”
It is often just missed, because we measure the wrong milestones.
Scale and blind spot
In the US, about 47% of CVD deaths occur in women. Many women and clinicians still under-recognize CVD as the leading threat.
Traditional risk factors behave differently in women
Type 2 diabetes confers about 25–50% higher CVD risk in women vs men.
Blood pressure rises faster with age in women; oral contraceptives increase hypertension risk by 13% per 5 years of use.
Obesity patterns differ: visceral and ectopic fat can drive higher risk in women even when BMI looks “acceptable”.
Female-specific risk enhancers are common and actionable
Autoimmune disease increases incident CVD risk: HR 1.56.
Endometriosis: 23% higher CVD risk.
Uterine leiomyomas: 32% higher MI risk, attenuated after surgical treatment.
Hypertensive disorders of pregnancy: 2 to 7.7× higher IHD risk; severe preeclampsia: 41.5% have elevated BP at 1 year postpartum.
PCOS: cardiometabolic clustering and 41% higher non-fatal cerebrovascular risk signal.
Clinical takeaway
Treat pregnancy and reproductive history as a cardiovascular stress test and a risk label.
Move beyond BMI: add waist metrics and consider subclinical atherosclerosis imaging when risk remains uncertain.
Build multidisciplinary pathways: OB-GYN, endocrinology, rheumatology, and cardiology should share a unified prevention pathway for women across the lifespan.
Disclaimer
The views and opinions expressed in my posts are solely my own, made in my capacity as a private individual, medical doctor, and researcher. They do not represent or reflect the views, policies, or positions of my employer, colleagues, or any affiliated organizations. My posts are intended for informational and discussion purposes only.”
Title: Cardiovascular disease in women: traditional and sex-specific risk factors
Authors: Yolande Appelman, Martha Gulati, Jeanine E Roeters van Lennep, Leslee J Shaw, C Noel Bairey Merz
Read full article here.
Get insights from Hemostasis Today.
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means.
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC